Induction of CD69 antigen expression in peripheral blood mononuclear cells on exposure to silica, but not by asbestos/chrysotile-A

Immunology Letters

Volumn 98, Issue 1, 2005, Pages 145-152

  Wu, Ping ^a,b   Hyodoh, Fuminori ^a   Hatayama, Tamayo ^a   Sakaguchi, Haruko ^a   Hatada, Satomi ^a   Miura, Yoshie ^a   Takata Tomokuni, Akiko ^a   Katsuyama, Hironobu ^a   Otsuki, Takemi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Asbestos; CD69; PKC; Silica

Indexed keywords

ASBESTOS; CD69 ANTIGEN; CHRYSOTILE; CYCLIC AMP DEPENDENT PROTEIN KINASE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; SILICON DIOXIDE;

ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CELL CONTACT; CELL CULTURE; CELL INTERACTION; CELL SURVIVAL; CYTOKINE PRODUCTION; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE SYSTEM; MONONUCLEAR CELL; PATIENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 15744386373     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2004.11.005     Document Type: Article

References (37)

1. S. Iannello, M. Camuto, S. Cantarella, A. Cavaleri, P. Ferriero, A. Leanza, P. Milazzo, and F. Belfiore Rheumatoid syndrome associated with lung interstitial disorder in a dental technician exposed to ceramic silica dust. A case report and critical literature review Clin Rheumatol 21 2002 76 81
2. P. Stratta, C. Canavese, A. Messuerotti, I. Fenoglio, and B. Fubini Silica and renal diseases: no longer a problem in the 21st century? J Nephrol 14 2001 228 247
3. D.R. Shanklin, and D.L. Smalley The immunopathology of siliconosis. History, clinical presentation, and relation to silicosis and the chemistry of silicon and silicone Immunol Res 18 1998 125 173
4. K. Steenland, and D.F. Goldsmith Silica exposure and autoimmune diseases Am J Ind Med 28 1995 603 608
5. C.L. Uber, and R.A. McReynolds Immunotoxicology of silica Crit Rev Toxicol 10 1982 303 319
6. D.W. Cugell, and D.W. Kamp Asbestos and the pleura: a review Chest 125 2004 1103 1117
7. H.D. Roach, G.J. Davies, R. Attanoos, M. Crane, H. Adams, and S. Phillips Asbestos: when the dust settles an imaging review of asbestos-related disease Radiographics 22 2002 [Spec No: S167-84]
8. C. Bolton, A. Richards, and P. Ebden Asbestos-related disease Hosp Med 63 2002 148 151
9. C.G. Billings, and P. Howard Asbestos exposure, lung cancer and asbestosis Monaldi Arch Chest Dis 55 2000 151 156
10. A. Ueki Biological effects of asbestos fibers on human cells in vitro - especially on lymphocytes and neutrophils Ind Health 39 2001 84 93
11. T. Otsuki, A. Takata, F. Hyodoh, A. Ueki, Y. Matsuo, and M. Kusaka Dysregulation of Fas-mediated apoptotic pathway in silicosis patients Rec Res Develop Immunol 4 2002 703 713
12. K.V. Prasad, and B.S. Prabhakar Apoptosis and autoimmune disorders Autoimmunity 36 2003 323 330
13. F. Rieux-Laucat, A. Fischer, and F.L. Deist Cell-death signaling and human disease Curr Opin Immunol 15 2003 325 331
14. S. Yonehara Death receptor Fas and autoimmune disease: from the original generation to therapeutic application of agonistic anti-Fas monoclonal antibody Cytokine Growth Factor Rev 13 2002 393 402
15. I.R. Rifkin, and A. Marshak-Rothstein Fas and Fas ligand in autoimmunity Curr Dir Autoimmun 1 1999 31 55
16. A. Tomokuni, T. Aikoh, T. Matsuki, T. Otsuki, S. Kita, and H. Ueki Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours Clin Exp Immunol 110 1997 303 309
17. T. Otsuki, H. Sakaguchi, A. Tomokuni, T. Aikoh, T. Matsuki, and Kawakani Soluble Fas mRNA is dominantly expressed in cases with silicosis Immunology 94 1998 258 262
18. T. Otsuki, A. Tomokuni, H. Sakaguchi, T. Aikoh, T. Matsuki, and Y. Isozaki Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients Clin Exp Immunol 119 2000 323 327
19. T. Otsuki, K. Ichihara, A. Tomokuni, H. Sakaguchi, T. Aikoh, and T. Matsuki Evaluation of cases with silicosis using the parameters related to Fas-mediated apoptosis Int J Mol Med 4 1999 407 411
20. A. Ueki, Y. Isozaki, A. Tomokuni, T. Hatayama, H. Ueki, and M. Kusaka Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals Clin Exp Immunol 129 2002 556 561
21. A. Ueki, Y. Isozaki, A. Tomokuni, H. Ueki, M. Kusaka, and S. Tanaka Different distribution of HLA class II alleles in anti-topoisomerase I autoantibody responders between silicosis and systemic sclerosis patients, with a common distinct amino acid sequence in the HLA-DQB1 domain Immunobiology 204 2001 458 465
22. A. Ueki, Y. Isozaki, A. Tomokuni, S. Tanaka, T. Otsuki, and T. Kishimoto Autoantibodies detectable in the sera of silicosis patients. The relationship between the anti-topoisomerase I antibody response and HLA-DQB1*0402 allele in Japanese silicosis patients Sci Total Environ 270 2001 141 148
23. H. Ueki, M. Kohda, T. Nobutoh, M. Yamaguchi, K. Omori, and Y. Miyashita Antidesmoglein autoantibodies in silicosis patients with no bullous diseases Dermatology 202 2001 16 21
24. A. Tomokuni, T. Otsuki, H. Sakaguchi, Y. Isozaki, F. Hyodoh, M. Kusaka, and A. Ueki Detection of anti-topoisomerase I autoantibody in patients with silicosis Environ Health Prev Med 7 2002 7 10
25. W. Peters Silicone breast implants and autoimmune connective tissue disease Ann Plast Surg 34 1995 103 109
26. H. Hirmand, G.S. Latrenta, and L.A. Hoffman Autoimmune disease and silicone breast implants Oncology (Huntingt) 7 1993 17 24
27. D.M. Duffy Silicone: a critical review Adv Dermatol 5 1990 93 107
28. K. Yata, T. Otsuki, J. Kurebayashi, M. Uno, T. Fujii, and Y. Yawata Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells Int J Oncol 22 2003 165 173
29. M. Uno, T. Otsuki, J. Kurebayashi, H. Sakaguchi, Y. Isozaki, and A. Ueki Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma Int J Cancer 94 2001 474 479
30. H. Zola Markers of cell lineage, differentiation and activation J Biol Regul Homeost Agents 14 2000 218 219
31. R. Marzio, J. Mauel, and S. Betz-Corradin CD69 and regulation of the immune function Immunopharmacol Immunotoxicol 21 1999 565 582
32. S.F. Ziegler, F. Ramsdell, and M.R. Alderson The activation antigen CD69 Stem Cells 12 1994 456 465
33. D. Portales-Perez, R. Gonzalez-Amaro, C. Abud-Mendoza, and S. Sanchez-Armass Abnormalities in CD69 expression, cytosolic pH and Ca2+ during activation of lymphocytes from patients with systemic lupus erythematosus Lupus 6 1997 48 56
34. E.M. Genot, P.J. Parker, and D.A. Cantrell Analysis of the role of protein kinase C-alpha, -epsilon, and -zeta in T cell activation J Biol Chem 270 1995 9833 9839
35. P. Vandenberghe, J. Verwilghen, F. Van Vaeck, and J.L. Ceuppens Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism Immunology 78 1993 210 217
36. A.G. Santis, M.R. Campanero, J.L. Alonso, A. Tugores, M.A. Alonso, E. Yague, J.P. Pivel, and F. Sanchez-Madrid Tumor necrosis factor-alpha production induced in T lymphocytes through the AIM/CD69 activation pathway Eur J Immunol 22 1992 1253 1259
37. R. Testi, J.H. Phillips, and L.L. Lanier T cell activation via Leu-23 (CD69) J Immunol 143s 1989 1123 1128